中文摘要：

脉络膜新生血管（choroidal neovascularization,CNV）主要继发于年龄相关性黄斑变性（age-related maculard egeneration,AMD）,严重影响中心视力,甚至致盲。目前,以光敏剂维替泊芬介导的光动力疗法（photodynamic therapy,PDT）治疗CNV取得了令人瞩目的效果。但由于维替泊芬价格昂贵等问题,临床应用受到一定限制。因此各国的学者均致力于新型光敏剂的研发,以期获得替代维替泊芬的效用,我们就应用于CNV治疗的光敏剂的研究进展作一综述。

英文摘要：

Choroidal neovascularization（CNV） mainly caused by age-related macular degeneration（AMD）,can lead to serious central vision effect,even blindness.At present,the photosensitizer Verteporfin mediated photodynamic therapy（PDT） on CNV achieved remarkable results.Because of the price,the clinical treatment is limited.So the scholars of many countries devoted to the research and development of new photosensitizer to obtain replacement for the utility of Verteporfin,this paper applied to the advanced study on the photosensitizer of PDT on CNV.